Lakewood-Amedex Begins Trading on NASDAQ#
Lakewood-Amedex Biotherapeutics Inc., a clinical-stage biotechnology firm based in Sarasota, Florida, has officially started trading on the Nasdaq Capital Market under the ticker symbol "LABT". This marks a significant milestone for the company as it aims to enhance the development of its innovative antimicrobial treatments.
Focus on Antimicrobial Treatments#
The company specializes in developing a class of antimicrobials known as Bisphosphocins, which are designed to combat infectious diseases. Their leading product, Nu-3, is specifically being developed for the topical treatment of infected diabetic foot ulcers. These ulcers are a serious complication for many individuals living with diabetes.
Importance of Diabetic Foot Ulcers#
According to Chief Executive Officer Kelvin Cooper, Ph.D., around 40 million people in the United States are affected by diabetes, and approximately one-third of these individuals will experience diabetic foot ulcers at some point in their lives. Alarmingly, about 50% of these ulcers can become infected, highlighting the need for effective treatments like Nu-3.
Clinical Trials Ahead#
Lakewood-Amedex plans to initiate a Phase 2a clinical trial for Nu-3, focusing on its safety and dosage response. This will be followed by a Phase 2b study that will compare the treatment against a placebo to determine the best administration method. The company’s research indicates that their Bisphosphocin class shows promise in eliminating bacteria, including those that are resistant to other treatments, and may improve wound healing outcomes.